RxDoctor Payments Data

Fanar Alyas, MD

Family Medicine · Wyandotte, MINPI 1932468097

Payments from drug & device makers

$7,309in general payments, 2019–2025

Across 471 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$840
  • AbbVie$713
  • Lilly USA, LLC$689
  • AstraZeneca$547
  • Bayer$453
  • GSK$427
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,309 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$209,039
Medicare patients
367
Services billed
2,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$94,033
EliquisApixaban57$64,822
MounjaroTirzepatide52$54,932
JardianceEmpagliflozin33$51,912
Xigduo XrDapaglifloz Propaned/Metformin26$32,169
FarxigaDapagliflozin Propanediol25$31,517
TrulicityDulaglutide26$29,168
EntrestoSacubitril/Valsartan40$28,913
RybelsusSemaglutide16$27,081
LinzessLinaclotide34$21,506
OzempicSemaglutide22$21,158
MyrbetriqMirabegron23$14,504
TrintellixVortioxetine Hydrobromide22$8,598
BelsomraSuvorexant12$4,920
Atorvastatin Calcium376$4,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$427$94,033106 claims
Lilly USA, LLCMounjaro, Trulicity$689$84,10078 claims
PfizerEliquis$425$64,82257 claims
Boehringer IngelheimJardiance$203$51,91233 claims
Novo NordiskRybelsus, Ozempic$840$48,23938 claims
AstraZenecaFarxiga$547$31,51725 claims
NovartisEntresto$144$28,91340 claims
AbbVieLinzess, Synthroid$713$22,46746 claims
Astellas Pharma US IncMyrbetriq$98$14,50423 claims
MerckBelsomra$341$4,92012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Wyandotte

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →